Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics
(NQ:
FOLD
)
10.50
+0.45 (+4.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amicus Therapeutics
< Previous
1
2
3
4
5
Next >
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
December 05, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
November 15, 2023
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
November 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
The Latest Analyst Ratings for Amicus Therapeutics
March 28, 2023
Via
Benzinga
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 27, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 03, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
October 02, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
September 28, 2023
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.
Via
Benzinga
Exposures
Product Safety
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
September 28, 2023
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Via
Investor's Business Daily
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
September 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 29, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
August 21, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
August 15, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 31, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
July 20, 2023
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.
Via
Investor's Business Daily
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
July 17, 2023
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier.
Via
Investor's Business Daily
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
June 27, 2023
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD)
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
May 19, 2023
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday.
Via
Investor's Business Daily
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
May 10, 2023
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult
Via
Benzinga
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 10, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
May 02, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
May 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
April 26, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
March 27, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
March 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.